Agenus Webcast to Spotlight Novel Cancer Drug Amid FDA Review

LEXINGTON, MA – March 26, 2026 – Immuno-oncology firm Agenus Inc. is poised to deliver a critical update on its lead cancer therapy, with stakeholders and the medical community watching closely as the company navigates the final stages of a potential U.S. regulatory approval. The company announced it will host a stakeholder webcast in March to detail the progress of its botensilimab and balstilimab (BOT+BAL) combination therapy, a treatment that has shown significant promise in cancers historically resistant to immunotherapy.

The event comes at a pivotal time for the Lexington-based company. Having submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for botensilimab in mid-2024, Agenus is now deep into the regulatory review cycle. The upcoming webcast is expected to provide the most current information on the therapy's clinical advancements, patient access programs, and the company's strategic priorities for 2026, all under the shadow of a looming FDA decision.

A New Front Against "Cold" Tumors

Agenus is targeting one of the most significant challenges in modern oncology: treating immunologically "cold" tumors. These are cancers, such as non-microsatellite instability-high (non-MSI-H) colorectal cancer and pancreatic cancer, that do not provoke a strong immune response and thus remain largely invisible to blockbuster immunotherapies like PD-1 inhibitors.

The BOT+BAL combination is engineered to overcome this resistance. Balstilimab (BAL) is a PD-1 inhibitor, a well-established class of drug that helps the immune system's T cells recognize and attack cancer. However, the program's cornerstone is botensilimab (BOT), a next-generation CTLA-4 inhibitor. Its novel design, featuring an Fc-enhanced structure, is intended not only to block the CTLA-4 checkpoint but also to actively prime the immune system, boost T cell activation, and deplete suppressive regulatory T cells within the tumor. This multi-pronged attack is designed to turn "cold" tumors "hot," making them susceptible to an immune assault.

The clinical data generated so far has been a source of considerable optimism. In heavily pre-treated patients with non-MSI-H metastatic colorectal cancer—a population with dismal prognoses—the BOT+BAL combination demonstrated an objective response rate of 23% in Phase 2 trials. This figure is particularly noteworthy in a disease where single-agent immunotherapy has shown little to no benefit. Promising activity has also been observed in other difficult-to-treat malignancies, including pancreatic cancer, melanoma, and sarcoma, with approximately 1,200 patients having been treated across the program's clinical trials.

During the webcast, Chief Medical Officer Dr. Steven J. O’Day is expected to provide a detailed clinical perspective on the durability and consistency of these responses, highlighting how the data are shaping later-stage trials and the overall development strategy.

Navigating the High-Stakes Regulatory Pathway

For Agenus and its investors, the most pressing question revolves around the status of botensilimab's BLA with the FDA. The application, filed for the treatment of non-MSI-H metastatic colorectal cancer, was granted Fast Track designation, a program designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.

By March 2026, the review process is well underway. Observers are keenly awaiting updates on the assigned Prescription Drug User Fee Act (PDUFA) date—the FDA's deadline for a decision—and any communications from the agency. While the company has not publicly disclosed the exact timeline, the webcast, led by Founder and CEO Dr. Garo Armen, is the ideal platform to signal the program's standing with regulators.

Dr. Armen is slated to open the session by outlining the company's key priorities for 2026, a year that could see Agenus transition from a clinical-stage developer to a commercial entity. His remarks on the "urgency of advancing new options for patients" will resonate deeply with those following the botensilimab story, as a potential approval would represent a significant breakthrough for a large patient population with limited options.

Balancing Innovation with Global Patient Access

While navigating the rigorous U.S. approval process, Agenus has simultaneously pursued a strategy of early global access. This dual approach underscores the company's mission and provides invaluable real-world experience with the therapy.

A key component of this strategy is the Autorisation d'Accès Compassionnel (AAC) program in France, which grants pre-approval access to botensilimab for patients with advanced non-MSI-H colorectal cancer who have exhausted standard treatments. Alongside this, Agenus is utilizing Named Patient Programs (NPPs) to provide the drug on a compassionate use basis in other regions.

Dr. Kamel Djazouli, Head of Medical Affairs, will provide an update on these initiatives during the webcast. These programs not only offer a lifeline to patients in desperate need but also generate crucial real-world data on the therapy's safety and efficacy outside the controlled environment of a clinical trial. This information can be invaluable for informing physicians and potentially supporting future regulatory submissions and reimbursement discussions in different markets.

A Niche Opportunity in a Crowded Field

The immuno-oncology market is dominated by pharmaceutical giants like Merck and Bristol Myers Squibb, whose PD-1 and CTLA-4 inhibitors have become the standard of care in numerous cancers. Agenus is not positioning BOT+BAL to compete head-to-head across this broad landscape. Instead, its strategy is a focused one: to succeed where others have failed.

By generating compelling data in "cold" tumor indications, Agenus has carved out a distinct and valuable niche. The competitive advantage lies in botensilimab's unique mechanism, which appears to be effective in the very patient populations that derive little benefit from existing immunotherapies. This focused approach de-risks the commercial strategy by targeting a clear unmet need, which could facilitate market adoption and reimbursement if the therapy gains approval.

The upcoming webcast will provide a comprehensive look at how Agenus plans to leverage this unique position. As the company stands on the cusp of a potential landmark approval, the session will be scrutinized by patients, physicians, and investors alike, all eager to learn what the future holds for this promising new cancer therapy.